Is Compounded TB-500 (Thymosin Beta-4) Safe and Legal?
Compounded TB-500 (Thymosin Beta-4) is not currently available through Compounding Finder. TB-500 is not on the FDA 503A bulk drug substances list. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA has not acted, so US compounding pharmacies have no clear legal pathway to prepare it and Compounding Finder is not sending TB-500 quote requests to pharmacies.
Read the TB-500 (Thymosin Beta-4) background guide →The Short Answer
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US compounding pharmacies can only compound from FDA-approved active ingredients, substances with a USP or NF monograph, or substances on the FDA 503A bulk substances list. TB-500 (Thymosin Beta-4) meets none of these. An FDA advisory committee voted in July 2026 to recommend adding TB-500 to the list, but FDA has not acted, so there is no clear legal pathway for a licensed US compounding pharmacy to prepare or dispense it — even with a prescription. Products marketed as TB-500 (Thymosin Beta-4) outside this framework generally come from research-chemical suppliers and are not regulated for human use.
Who Is Eligible for Compounded TB-500 (Thymosin Beta-4)?
- There is no clinical eligibility pathway for TB-500 (Thymosin Beta-4) through 503A compounding at this time.
- If your prescriber has recommended TB-500 (Thymosin Beta-4), ask about FDA-approved alternatives that address the same condition.
- If FDA guidance changes and TB-500 (Thymosin Beta-4) is added to the 503A bulks list in the future, Compounding Finder will revisit routing.
Safety Considerations
- Only purchase prescription medications from U.S.-licensed compounding pharmacies for medications that are legally compoundable.
- Research-chemical peptide vendors and overseas "pharmacies" selling TB-500 (Thymosin Beta-4) for human use are not regulated — product identity, purity, sterility, and dosing are not verified.
- Any provider willing to prescribe or source a non-compoundable substance through these channels is operating outside the US 503A framework.
Red Flags: What to Avoid
- Any online clinic, telehealth provider, or vendor offering to "compound" or ship TB-500 (Thymosin Beta-4) for human use.
- Labeling that calls a product "research use only" or "not for human consumption" while simultaneously marketing it for human indications.
- Pharmacies that fulfill a prescription for an ingredient not on the FDA 503A bulks list — they are operating outside federal rules.
Frequently Asked Questions
Can any US compounding pharmacy prepare TB-500 (Thymosin Beta-4) for me?
Not on a clear legal footing. TB-500 (Thymosin Beta-4) is not on the FDA 503A bulk substances list, and licensed US 503A pharmacies may only compound from FDA-approved APIs, USP/NF monograph substances, or substances on that list. An FDA advisory committee voted in July 2026 to recommend adding TB-500, but until FDA acts on that vote there is no clear legal pathway for a 503A pharmacy to fill a TB-500 (Thymosin Beta-4) prescription.
What did the FDA advisory committee decide in July 2026?
In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding TB-500 to the 503A bulk drug substances list. FDA's own reviewers had recommended against it. The committee only advises FDA: adding a substance to the list takes FDA rulemaking, and as of October 2026 FDA has not proposed it. We will revisit routing if FDA acts.
Why is Compounding Finder not sending TB-500 (Thymosin Beta-4) quote requests to pharmacies?
We only refer patients to licensed US 503A pharmacies. Sending a TB-500 (Thymosin Beta-4) quote request to those pharmacies would put them in a position to either decline or to fill a prescription they are not legally permitted to fill. Neither outcome is useful to the patient, so we do not route these requests.
What should I do if my prescriber recommended this?
Ask them whether an FDA-approved medication addresses the same underlying condition — for many of these peptides there are FDA-approved alternatives worth discussing. If the recommendation came from a wellness or telehealth clinic that also sells the product, be skeptical; that is not the same regulatory channel as a licensed US 503A compounding pharmacy.
Keep Reading
Pharmacy basics: 503A vs 503B pharmacies — what's the difference? →
Vetting pharmacies: How to find a reputable compounding pharmacy →
We Do Not Currently Route TB-500 (Thymosin Beta-4) Quote Requests
Because of the FDA’s current stance on TB-500 (Thymosin Beta-4), Compounding Finder is not sending TB-500 (Thymosin Beta-4) quote requests to our pharmacy network at this time. If FDA guidance changes, we will revisit.